Role of oral factor Xa inhibitors after acute coronary syndrome

Abhishek Sharma, Akash Garg, Jeffrey S. Borer, Parasuram Krishnamoorthy, Jalaj Garg, Carl J. Lavie, Armin Zadeh, Debabrata Mukherjee, Hasan Ahmad, Edgar Lichstein

Research output: Contribution to journalArticle

Abstract

Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic events, but the overall benefits were offset by increased bleeding complications. Recently, there has been increased interest in the potential role of new oral anticoagulants, some of which target factor Xa, after ACS. Factor Xa is important for the coagulation pathway and also plays a role in cellular proliferation and inflammation. It may thus be an attractive target for therapeutic intervention in ACS. Recently, various oral factor Xa inhibitors have been studied as potential treatment options for ACS. This review will focus on currently available data to evaluate the possible role of factor Xa inhibitors in the management of patients with ACS.

Original languageEnglish (US)
Pages (from-to)224-232
Number of pages9
JournalCardiology
Volume129
Issue number4
DOIs
StatePublished - Apr 16 2014

Fingerprint

Acute Coronary Syndrome
Factor Xa
Warfarin
Anticoagulants
Factor Xa Inhibitors
Therapeutics
Cell Proliferation
Hemorrhage
Inflammation

Keywords

  • Acute coronary syndrome
  • Coagulation pathway
  • Factor Xa

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Sharma, A., Garg, A., Borer, J. S., Krishnamoorthy, P., Garg, J., Lavie, C. J., ... Lichstein, E. (2014). Role of oral factor Xa inhibitors after acute coronary syndrome. Cardiology, 129(4), 224-232. https://doi.org/10.1159/000368747

Role of oral factor Xa inhibitors after acute coronary syndrome. / Sharma, Abhishek; Garg, Akash; Borer, Jeffrey S.; Krishnamoorthy, Parasuram; Garg, Jalaj; Lavie, Carl J.; Zadeh, Armin; Mukherjee, Debabrata; Ahmad, Hasan; Lichstein, Edgar.

In: Cardiology, Vol. 129, No. 4, 16.04.2014, p. 224-232.

Research output: Contribution to journalArticle

Sharma, A, Garg, A, Borer, JS, Krishnamoorthy, P, Garg, J, Lavie, CJ, Zadeh, A, Mukherjee, D, Ahmad, H & Lichstein, E 2014, 'Role of oral factor Xa inhibitors after acute coronary syndrome', Cardiology, vol. 129, no. 4, pp. 224-232. https://doi.org/10.1159/000368747
Sharma A, Garg A, Borer JS, Krishnamoorthy P, Garg J, Lavie CJ et al. Role of oral factor Xa inhibitors after acute coronary syndrome. Cardiology. 2014 Apr 16;129(4):224-232. https://doi.org/10.1159/000368747
Sharma, Abhishek ; Garg, Akash ; Borer, Jeffrey S. ; Krishnamoorthy, Parasuram ; Garg, Jalaj ; Lavie, Carl J. ; Zadeh, Armin ; Mukherjee, Debabrata ; Ahmad, Hasan ; Lichstein, Edgar. / Role of oral factor Xa inhibitors after acute coronary syndrome. In: Cardiology. 2014 ; Vol. 129, No. 4. pp. 224-232.
@article{f50f38d5371646c6a8c14796eda402e6,
title = "Role of oral factor Xa inhibitors after acute coronary syndrome",
abstract = "Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic events, but the overall benefits were offset by increased bleeding complications. Recently, there has been increased interest in the potential role of new oral anticoagulants, some of which target factor Xa, after ACS. Factor Xa is important for the coagulation pathway and also plays a role in cellular proliferation and inflammation. It may thus be an attractive target for therapeutic intervention in ACS. Recently, various oral factor Xa inhibitors have been studied as potential treatment options for ACS. This review will focus on currently available data to evaluate the possible role of factor Xa inhibitors in the management of patients with ACS.",
keywords = "Acute coronary syndrome, Coagulation pathway, Factor Xa",
author = "Abhishek Sharma and Akash Garg and Borer, {Jeffrey S.} and Parasuram Krishnamoorthy and Jalaj Garg and Lavie, {Carl J.} and Armin Zadeh and Debabrata Mukherjee and Hasan Ahmad and Edgar Lichstein",
year = "2014",
month = "4",
day = "16",
doi = "10.1159/000368747",
language = "English (US)",
volume = "129",
pages = "224--232",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "4",

}

TY - JOUR

T1 - Role of oral factor Xa inhibitors after acute coronary syndrome

AU - Sharma, Abhishek

AU - Garg, Akash

AU - Borer, Jeffrey S.

AU - Krishnamoorthy, Parasuram

AU - Garg, Jalaj

AU - Lavie, Carl J.

AU - Zadeh, Armin

AU - Mukherjee, Debabrata

AU - Ahmad, Hasan

AU - Lichstein, Edgar

PY - 2014/4/16

Y1 - 2014/4/16

N2 - Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic events, but the overall benefits were offset by increased bleeding complications. Recently, there has been increased interest in the potential role of new oral anticoagulants, some of which target factor Xa, after ACS. Factor Xa is important for the coagulation pathway and also plays a role in cellular proliferation and inflammation. It may thus be an attractive target for therapeutic intervention in ACS. Recently, various oral factor Xa inhibitors have been studied as potential treatment options for ACS. This review will focus on currently available data to evaluate the possible role of factor Xa inhibitors in the management of patients with ACS.

AB - Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic events, but the overall benefits were offset by increased bleeding complications. Recently, there has been increased interest in the potential role of new oral anticoagulants, some of which target factor Xa, after ACS. Factor Xa is important for the coagulation pathway and also plays a role in cellular proliferation and inflammation. It may thus be an attractive target for therapeutic intervention in ACS. Recently, various oral factor Xa inhibitors have been studied as potential treatment options for ACS. This review will focus on currently available data to evaluate the possible role of factor Xa inhibitors in the management of patients with ACS.

KW - Acute coronary syndrome

KW - Coagulation pathway

KW - Factor Xa

UR - http://www.scopus.com/inward/record.url?scp=84911481047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911481047&partnerID=8YFLogxK

U2 - 10.1159/000368747

DO - 10.1159/000368747

M3 - Article

C2 - 25402219

AN - SCOPUS:84911481047

VL - 129

SP - 224

EP - 232

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 4

ER -